Anavex Life Sciences (AVXL) Long-Term Deferred Tax (2015 - 2025)

Anavex Life Sciences (AVXL) has 11 years of Long-Term Deferred Tax data on file, last reported at $54.8 million in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Deferred Tax rose 262.6% year-over-year to $54.8 million; the trailing twelve-month figure through Sep 2025 stood at $54.8 million (up 262.6% YoY), and the FY2025 full-year result was $54.8 million, up 262.6% from the prior year.
• Long-Term Deferred Tax improved to $54.8 million in Q3 2025, from $15.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $54.8 million in Q3 2025 to a low of $15.1 million in Q3 2024.
• A 5-year average of $39.5 million and a median of $46.2 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax slumped 67.5% in 2024 and jumped 262.6% in 2025, its largest moves.
• Tracing AVXL's Long-Term Deferred Tax over 5 years: stood at $35.0 million in 2021, then jumped by 32.09% to $46.2 million in 2022, then grew by 0.55% to $46.5 million in 2023, then slumped by 67.5% to $15.1 million in 2024, then jumped by 262.6% to $54.8 million in 2025.
• Business Quant data shows AVXL's Long-Term Deferred Tax at $54.8 million in Q3 2025, $15.1 million in Q3 2024, and $46.5 million in Q3 2023.